Search

Your search keyword '"Nuciforo, Paolo"' showing total 24 results

Search Constraints

Start Over You searched for: Author "Nuciforo, Paolo" Remove constraint Author: "Nuciforo, Paolo" Database Springer Nature Journals Remove constraint Database: Springer Nature Journals
24 results on '"Nuciforo, Paolo"'

Search Results

1. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models

2. Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patients

5. RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

6. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

7. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

8. pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation

9. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

11. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

12. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

13. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

14. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment

15. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

17. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

18. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

20. The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation

24. Erratum To: The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation

Catalog

Books, media, physical & digital resources